Cortexin vs Semax

Overview

Cortexin and Semax are both Russian neuropeptide preparations used clinically in Russia for cognitive and neurological conditions. However, they differ fundamentally: Cortexin is a polypeptide complex extracted from pig or calf cerebral cortex, while Semax is a defined synthetic heptapeptide based on ACTH(4-10) with proven BDNF-modulating activity.

This comparison helps researchers understand the differences between complex extract approaches and defined synthetic peptides in cognitive research.

Key Facts

Aspect	Cortexin	Semax
Type	Polypeptide complex	Defined heptapeptide
Structure	Multiple peptides (1-10 kDa)	7 amino acids (Met-Glu-His-Phe-Pro-Gly-Pro)
Origin	Animal cerebral cortex	Synthetic (ACTH fragment)
Molecular Weight	1,000-10,000 Da range	813.92 Da
Russian Approval	Yes	Yes
FDA Status	Not approved	Not approved

Development History

Aspect	Cortexin	Semax
Developed	1980s (Russia)	1980s (Russia)
Institute	St. Petersburg	Institute of Molecular Genetics
Approach	Tissue extract	Synthetic design
Base	Animal brain tissue	ACTH(4-7) + Pro-Gly-Pro

Mechanism Comparison

Aspect	Cortexin	Semax
Primary Mechanism	Neurotrophic support	BDNF upregulation
Receptor	Unknown/multiple	Melanocortin receptors (partial)
BDNF Effect	Claimed	Confirmed
NGF Effect	Claimed	Confirmed
Antioxidant	Yes (claimed)	Yes (confirmed)

Cortexin Proposed Mechanisms

1. Neurotrophic Support

   • Contains multiple neuropeptides
   • Claimed growth factor effects
   • General “nutritive” support

2. Antioxidant Activity

   • Proposed free radical scavenging
   • Neuroprotection claims
   • Mechanism not well-defined

3. Neurotransmitter Modulation

   • Balance restoration claimed
   • GABAergic effects proposed
   • Glutamate regulation claimed

Semax Established Mechanisms

1. BDNF Upregulation

   • Well-documented in studies
   • 1.5-2x increases observed
   • NGF and GDNF also increased

2. Melanocortin Receptor Activity

   • MC3/MC4 receptor binding
   • Neuroprotective signaling
   • Anti-inflammatory effects

3. Neurotransmitter Modulation

   • Dopamine and serotonin effects
   • Documented in research
   • Mechanism characterized

Evidence Quality

Factor	Cortexin	Semax
Human Studies	Multiple (Russian)	Multiple (Russian)
Mechanistic Studies	Limited	Extensive
Western Research	Very limited	Growing
Publication Quality	Variable	Higher
Overall Evidence	Low	Low-Moderate

Cortexin Research

Study Type	Availability	Quality
Russian clinical trials	Multiple	Variable methodology
Mechanistic studies	Limited	Low
Pediatric studies	Several	Low-Moderate
Stroke rehabilitation	Several	Low-Moderate

Semax Research

Study Type	Availability	Quality
BDNF studies	Multiple	Moderate
Mechanistic studies	Extensive	Moderate
Clinical studies (Russia)	Multiple	Low-Moderate
Western research	Growing	Moderate

Clinical Applications (Russia)

Cortexin Indications

Condition	Use	Evidence Quality
Stroke recovery	Common	Low-Moderate
TBI rehabilitation	Common	Low
Cognitive impairment	Common	Low
Pediatric neurology	Common	Low-Moderate
Encephalopathy	Approved	Low

Semax Indications

Condition	Use	Evidence Quality
Cognitive enhancement	Approved (Russia)	Low-Moderate
Stroke (acute/recovery)	Approved (Russia)	Low-Moderate
Optic nerve disorders	Approved (Russia)	Low
ADHD	Studied	Very Low

Administration

Aspect	Cortexin	Semax
Route	Intramuscular	Intranasal
Duration	10-day courses	Days to weeks
Convenience	Requires injection	Self-administered drops

Administration Comparison

Factor	Cortexin	Semax
Self-Administration	Difficult (IM)	Easy (nasal)
Compliance	May require clinic	Home use possible
Invasiveness	Injection required	Non-invasive
Stability	Refrigeration needed	Room temp possible

Side Effect Profiles

Cortexin

Effect	Frequency	Notes
Injection site pain	Common	IM administration
Headache	Occasional	Usually mild
Generally well-tolerated	Yes	Russian clinical experience

Semax

Effect	Frequency	Notes
Nasal irritation	Occasional	Mild, transient
Hair loss (chronic use)	Reported	Anecdotal, reversible
Generally well-tolerated	Yes	Russian clinical experience

Quality and Standardization

Cortexin Concerns

Issue	Impact
Batch variability	Composition differs
Animal origin	Theoretical contamination risk
Active components	Not fully identified
Standardization	Challenging

Semax Advantages

Factor	Benefit
Defined structure	Consistent product
Synthetic	No animal-derived risks
Mechanism known	Predictable effects
Quality control	Easier verification

Regulatory Status

Aspect	Cortexin	Semax
Russia	Approved	Approved
Ukraine	Approved	Approved
FDA	Not approved	Not approved
EMA	Not approved	Not approved
Western Availability	Research chemical	Research chemical

Scientific Credibility

Factor	Cortexin	Semax
Mechanism Understanding	Poor	Moderate
Reproducibility	Difficult	Better
Western Research	Minimal	Growing
Publication Quality	Variable	Higher
Academic Interest	Limited	Increasing

Comparison for Different Needs

For Cognitive Research

Factor	Cortexin	Semax
Mechanism clarity	Low	Moderate
Reproducibility	Challenging	Better
BDNF data	Limited	Strong
Research utility	Limited	Higher

For Clinical Application Research

Factor	Cortexin	Semax
Administration	Injection required	Nasal (easier)
Compliance	Harder	Easier
Russian experience	Extensive	Extensive
Standardization	Poor	Good

Cost and Availability

Factor	Cortexin	Semax
Russian pharmaceutical	Available	Available
Western research grade	Limited	Available
Relative cost	Moderate	Lower
Quality verification	Difficult	Easier

Summary

Factor	Cortexin	Semax
Structure	Polypeptide complex	Defined heptapeptide
Origin	Animal brain extract	Synthetic
Mechanism	Unclear/multiple	BDNF/melanocortin
Evidence Level	Moderate	Moderate
Standardization	Poor	Good
Administration	Injection (IM)	Nasal drops
Western Research	Minimal	Growing

Key Takeaways

1. Different approaches: Cortexin is complex extract; Semax is defined synthetic peptide
2. Semax has clearer mechanism: BDNF upregulation well-documented; cortexin mechanism unclear
3. Standardization differs: Semax reproducible; cortexin composition variable
4. Administration convenience: Semax nasal drops vs cortexin injections
5. Both Russian-approved: Extensive clinical use in Russia for both
6. Neither Western-approved: Both are research chemicals in Western countries
7. Growing Semax interest: More Western research on Semax than cortexin
8. Quality concerns: Cortexin animal origin vs Semax synthetic

---

This comparison is for educational purposes only. Neither peptide is approved by Western regulatory agencies. Both are approved in Russia but available only as research chemicals in Western countries.